AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Scilex Holding Company: Merger Agreement Amended, Adds Russell Indexes, Reports Earnings, and Announces FDA Approval
ByAinvest
Wednesday, Jul 23, 2025 8:28 am ET1min read
Scilex Holding Company has amended its merger agreement with Denali Capital and added to several Russell indexes. The company has also reported earnings results for Q1 2025 and regained compliance with Nasdaq listing rules. Scilex received FDA orphan drug designation for its version of colchicine and approval for ELYXYB's acute treatment of migraine in Canada. The company also implemented a 1-for-35 reverse stock split and terminated a sales agreement with B. Riley, Cantor Fitzgerald, and H.C. Wainwright.
Scilex Holding Company (NasdaqCM: SCLX) has made significant strides in recent months, with notable developments including the amendment of its merger agreement with Denali Capital, additions to several Russell indexes, and strong earnings reports. The company also received FDA orphan drug designation for its version of colchicine and approval for ELYXYB's acute treatment of migraine in Canada. Additionally, Scilex implemented a 1-for-35 reverse stock split and terminated a sales agreement with B. Riley, Cantor Fitzgerald, and H.C. Wainwright.Merger Agreement Amendment and Index Additions
Scilex Holding Company amended its merger agreement with Denali Capital, pushing the deadline with extra funding [1]. The company was also added to several Russell indexes, including the Russell Microcap Growth Index, Russell Microcap Index, Russell 3000E Growth Index, and Russell 3000E Index, effective June 29, 2025 [1].
Earnings Reports and FDA Approvals
Scilex reported its earnings results for the first quarter ended March 31, 2025, and regained compliance with Nasdaq listing rules, leading to a rise in shares [1]. The company received FDA orphan drug designation for its version of colchicine for the treatment of pericarditis [1]. Additionally, Scilex's ELYXYB received approval for its acute treatment of migraine in Canada from Health Canada's Pharmaceutical Drugs Directorate [1].
Reverse Stock Split and Sales Agreement Termination
Scilex implemented a 1-for-35 reverse stock split, which was announced on April 11, 2025 [1]. The company also terminated its sales agreement with B. Riley, Cantor Fitzgerald, and H.C. Wainwright, effective March 5, 2025 [1].
References
[1] https://www.marketscreener.com/news/scilex-holding-co-amends-merger-agreement-with-denali-capital-ce7c5cd2da8ef227
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet